EGFR Gene Mutation Clinical Trials

10 recruiting

EGFR Gene Mutation Trials at a Glance

10 actively recruiting trials for egfr gene mutation are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in San Francisco, Boston, and Bologna. Lead sponsors running egfr gene mutation studies include China Medical University Hospital, Collin Blakely, and Apollomics Inc..

Browse egfr gene mutation trials by phase

Treatments under study

About EGFR Gene Mutation Clinical Trials

Looking for clinical trials for EGFR Gene Mutation? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EGFR Gene Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EGFR Gene Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Not Applicable

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung CancerBrain MetastasesEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico74 enrolled1 locationNCT06238882
Recruiting
Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Not Applicable

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Lung CancerEGFR Gene Mutation
Dana-Farber Cancer Institute1,000 enrolled6 locationsNCT06716580
Recruiting
Phase 2

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Not Applicable

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Henan Cancer Hospital60 enrolled2 locationsNCT06643000
Recruiting
Phase 1Phase 2

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation
China Medical University Hospital20 enrolled1 locationNCT06071013
Recruiting
Phase 1

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer MetastaticEGFR Gene Mutation
Collin Blakely38 enrolled1 locationNCT04085315
Recruiting
Phase 2

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China96 enrolled1 locationNCT05503667
Recruiting
Not Applicable

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Non-small Cell Lung CancerNSCLCBrain Metastases+2 more
Hadassah Medical Organization162 enrolled1 locationNCT05033691